MII IG Kerndatensatz-Modul Molekulares Tumorboard
2027.0.0-ballot.1 - Germany

This page is part of the MII Implementation Guide Molecular Tumor Board (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

Example RequestGroup: Adavosertib +/- Carboplatin

English

Profile: MII PR MTB Therapieempfehlung Kombinationstherapie version: 2027.0.0-ballot.1

MII EX MTB Empfehlung Priorität: 4

MII EX MTB Empfehlung Evidenzgraduierung: Predictive value of the biomarker or clinical effectiveness of the drug in a molecularly stratified cohort was demonstrated in a retrospective cohort or case–control study in the same tumor type.

MII EX MTB Empfehlung Publikation: http://www.ncbi.nlm.nih.gov/pubmed/37236033

status: Draft

intent: Proposal

code: Chemotherapie + zielgerichtete Substanzen

subject: Kim Musterperson (no stated gender), DoB: 1956-03-14

authoredOn: 2023-03-28

Actions

-Resource
*MedicationRequest: status = draft; intent = option; medication[x] = Carboplatin; authoredOn = 2023-03-28